Reply to M. Di Maio and F. Perrone [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Zhang, Liang, Hu Tags: CORRESPONDENCE Source Type: research

Subgroup Analysis: Refining a Positive Result or Trying to Rescue a Negative One? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Di Maio, Perrone Tags: CORRESPONDENCE Source Type: research

Incognito [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Langer Tags: End of life issues, Emotions of the oncologist, Ethics and legal issues, All Art of Oncology Articles Source Type: research

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study [Gynecologic Cancer]
Conclusion Combined MSI, methylation, and IHC analysis may prove useful in Lynch screening in EC. Twenty-four percent of mutation carriers presented with ECs at age> 60 years, and one carrier had an MSI-positive tumor with no IHC defect. Restricting Lynch testing to women diagnosed at age
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Goodfellow, Billingsley, Lankes, Ali, Cohn, Broaddus, Ramirez, Pritchard, Hampel, Chassen, Simmons, Schmidt, Gao, Brinton, Backes, Landrum, Geller, DiSilvestro, Pearl, Lele, Powell, Zaino, Mutch Tags: Combined Modality Gynecologic Cancer Source Type: research

Lavage of the Uterine Cavity for Molecular Detection of Mullerian Duct Carcinomas: A Proof-of-Concept Study [Gynecologic Cancer]
Conclusion This study proved that tumor cells from ovarian neoplasms are shed and can be collected via lavage of the uterine cavity. Detection of OC and EC and even clinically occult OC was achieved, making it a potential tool of significant promise for early diagnosis. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Maritschnegg, Wang, Pecha, Horvat, Van Nieuwenhuysen, Vergote, Heitz, Sehouli, Kinde, Diaz, Papadopoulos, Kinzler, Vogelstein, Speiser, Zeillinger Tags: Diagnosis & Staging, Diagnosis & Staging Gynecologic Cancer Source Type: research

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer [Gastrointestinal Cancer]
Conclusion The addition of vismodegib to gemcitabine in an unselected cohort did not improve overall response rate, PFS, or OS in patients with metastatic PC. Our preclinical and clinical results revealed no statistically significant differences with respect to drug delivery or treatment efficacy using vismodegib. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Catenacci, Junttila, Karrison, Bahary, Horiba, Nattam, Marsh, Wallace, Kozloff, Rajdev, Cohen, Wade, Sleckman, Lenz, Stiff, Kumar, Xu, Henderson, Takebe, Salgia, Wang, Stadler, de Sauvage, Kindler Tags: Clinical Trials, Chemotherapy, Translational Oncology, Gastrointestinal Gastrointestinal Cancer Source Type: research

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas [Sarcomas]
We report on a planned interim analysis. Results A total of 908 patients were randomly assigned between December 2004 and October 2008: 454 to imatinib and 454 to observation. Of these, 835 patients were eligible. With a median follow-up of 4.7 years, 5-year IFFS was 87% in the imatinib arm versus 84% in the control arm (hazard ratio, 0.79; 98.5% CI, 0.50 to 1.25; P = .21); RFS was 84% versus 66% at 3 years and 69% versus 63% at 5 years (log-rank P
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Casali, Le Cesne, Poveda Velasco, Kotasek, Rutkowski, Hohenberger, Fumagalli, Judson, Italiano, Gelderblom, Adenis, Hartmann, Duffaud, Goldstein, Broto, Gronchi, Dei Tos, Marreaud, van der Graaf, Zalcberg, Litiere, Blay Tags: Surgery, Chemotherapy, Combined Modality Sarcomas Source Type: research

Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base [Breast Cancer]
Purpose To explore racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer. Methods The National Cancer Data Base was queried to identify women with stage 1 to 3 breast cancer diagnosed in 2010 and 2011. Chemotherapy use and rate of pathologic complete response (pCR) was determined for various racial/ethnic groups. Results Of 278,815 patients with known race and ethnicity, 127,417 (46%) received chemotherapy, and of 121,446 where the timing of chemotherapy was known, 27,300 (23%) received neoadjuvant chemotherapy. Chemotherapy, and neoadjuvant chemotherapy in particular, was given more fre...
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Killelea, Yang, Wang, Hayse, Mougalian, Horowitz, Chagpar, Pusztai, Lannin Tags: Epidemiology, Chemotherapy Breast Cancer Source Type: research

Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer [Breast Cancer]
Conclusion RS receipt was associated with reduced use of adjuvant chemotherapy and lower health care spending among women with breast cancer who were younger than 55. Conversely, among women 75 and older, RS testing was associated with a modest increase in chemotherapy use and slightly higher spending. From a population perspective, the impact of RS testing on breast cancer treatment and health care costs is much greater in younger women. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Epstein, Wong, Mitra, Vachani, Hin, Yang, Smith-McLallen, Armstrong, Groeneveld Tags: Chemotherapy, Cost Effectiveness Breast Cancer Source Type: research

Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Munster Study Group [Pediatric Oncology]
Purpose This retrospective cohort study aimed to determine the predictive relevance of clinical characteristics, additional cytogenetic aberrations, and cKIT and RAS mutations, as well as to evaluate whether specific treatment elements were associated with outcomes in pediatric t(8;21)-positive patients with acute myeloid leukemia (AML). Patients and Methods Karyotypes of 916 pediatric patients with t(8;21)-AML were reviewed for the presence of additional cytogenetic aberrations, and 228 samples were screened for presence of cKIT and RAS mutations. Multivariable regression models were used to assess the relevance of anthr...
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Klein, Kaspers, Harrison, Beverloo, Reedijk, Bongers, Cloos, Pession, Reinhardt, Zimmerman, Creutzig, Dworzak, Alonzo, Johnston, Hirsch, Zapotocky, De Moerloose, Fynn, Lee, Taga, Tawa, Auvrignon, Zeller, Forestier, Salgado, Balwierz, Popa, Rubnitz, Raimon Tags: Acute Non-Lymphoblastic Leukemia/MDS/CML Pediatric Oncology Source Type: research

Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer [Thoracic Oncology]
Purpose To investigate outcomes for elderly patients treated with chemotherapy (CT) alone versus chemoradiotherapy (CRT) in the modern era by using a large national database. Patients and Methods Elderly patients (age ≥ 70 years) with limited-stage small-cell lung cancer clinical stage I to III who received CT or CRT were identified in the National Cancer Data Base between 2003 and 2011. Hierarchical mixed-effects logistic regression with clustering by reporting facility was performed to identify factors associated with treatment selection. Overall survival (OS) of patients receiving CT versus CRT was compared by using...
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Corso, Rutter, Park, Lester-Coll, Kim, Wilson, Husain, Lilenbaum, Yu, Decker Tags: Small Cell, Radiation, Chemotherapy, Combined Modality Thoracic Oncology Source Type: research

Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Caywood, Kolb Tags: Acute Non-Lymphoblastic Leukemia/MDS/CML EDITORIALS Source Type: research

Limited-Stage Small-Cell Lung Cancer: An Age Limit for Combined Modality Therapy? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Bogart, Gajra Tags: Small Cell, Radiation, Chemotherapy, Combined Modality EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: van den Brom, Makelburg, Schroder, de Vries, Hospers Tags: Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to S.M. Sorscher and A.B. Hafeez Bhatti [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Jagsi, Griffith, Kurian, Morrow, Hamilton, Graff, Katz, Hawley Tags: CORRESPONDENCE Source Type: research

Discussing Genetic Testing With Patients With Breast Cancer in Developing Countries: Should We Be Judicious? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Hafeez Bhatti Tags: CORRESPONDENCE Source Type: research

Discussing the Implications of Genetic Testing With Patients [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Sorscher Tags: CORRESPONDENCE Source Type: research

Reply to R.A. Ferrer et al and B.W. Corn [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Bakitas, Dionne-Odom, Lyons, Dragnev Tags: CORRESPONDENCE Source Type: research

Palliative Care Versus Spiritual Care [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Corn Tags: CORRESPONDENCE Source Type: research

Leveraging Affective Science to Maximize the Effectiveness of Palliative Care [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Ferrer, Padgett Tags: CORRESPONDENCE Source Type: research

Making Peace With Cancer [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Voit, van Akkooi Tags: End of life issues, Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery [SPECIAL ARTICLES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Muggia, Bonetti, Hoeschele, Rozencweig, Howell Tags: Phase I and Clinical Pharmacology, Radiation, Chemotherapy, Chemotherapy, Chemotherapy, Chemotherapy, Chemotherapy, Chemotherapy, Radiation, Chemotherapy, Combined Modality, Chemotherapy, Combined Modality, Emesis, Osteosarcoma & Ewing Sarcomas:, Radiatio Source Type: research

Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia [REVIEW ARTICLES]
For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI granted regulatory approval, has been surpassed in terms of molecular responses by the second-generation TKIs nilotinib, dasatinib, and bosutinib. Recently, ponatinib was approved as the only TKI with activity against the T315I mutation. Although all TKIs are associated with nonhematologic adverse events (AEs), experience with imatinib suggested that toxicities are typically manageable and apparent early during drug development. Recent reports o...
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Moslehi, Deininger Tags: Chemotherapy REVIEW ARTICLES Source Type: research

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study [Head and Neck Cancer]
Conclusion Addition of lapatinib to chemoradiotherapy and its use as long-term maintenance therapy does not offer any efficacy benefits and had additional toxicity compared with placebo in patients with surgically treated high-risk SCCHN. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Harrington, Temam, Mehanna, D'Cruz, Jain, D'Onofrio, Manikhas, Horvath, Sun, Dietzsch, Dubinsky, Holeckova, El-Hariry, Franklin, Biswas-Baldwin, Legenne, Wissel, Netherway, Farrell, Ellis, Wang-Silvanto, Amonkar, Ahmed, Santillana, Bourhis Tags: Radiation, Chemotherapy, Combined Modality Head and Neck Cancer Source Type: research

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE) [Thoracic Oncology]
Conclusion The 5-year OS and PFS rates in randomly assigned patients with resectable stage III non–small-cell lung cancer were excellent with both treatments. Both are acceptable strategies for this good-prognosis group. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Eberhardt, Pottgen, Gauler, Friedel, Veit, Heinrich, Welter, Budach, Spengler, Kimmich, Fischer, Schmidberger, De Ruysscher, Belka, Cordes, Hepp, Lutke-Brintrup, Lehmann, Schuler, Jockel, Stamatis, Stuschke Tags: Combined Modality Thoracic Oncology Source Type: research

Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer [Gastrointestinal Cancer]
Purpose Colonoscopic surveillance is recommended for individuals with familial colorectal cancer (CRC). However, the appropriate screening interval has not yet been determined. The aim of this randomized trial was to compare a 3-year with a 6-year screening interval. Patients and Methods Individuals between ages 45 and 65 years with one first-degree relative with CRC age
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Hennink, van der Meulen-de Jong, Wolterbeek, Crobach, Becx, Crobach, van Haastert, ten Hove, Kleibeuker, Meijssen, Nagengast, Rijk, Salemans, Stronkhorst, Tuynman, Vecht, Verhulst, de Vos tot Nederveen Cappel, Walinga, Weinhardt, Westerveld, Witte, Wolter Tags: Clinical Trials Gastrointestinal Cancer Source Type: research

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [Gastrointestinal Cancer]
Conclusion The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer. These updated results support the use of FOLFOX in patients with stage III disease, including those with dMMR or BRAF mutation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Andre, de Gramont, Vernerey, Chibaudel, Bonnetain, Tijeras-Raballand, Scriva, Hickish, Tabernero, Van Laethem, Banzi, Maartense, Shmueli, Carlsson, Scheithauer, Papamichael, Moehler, Landolfi, Demetter, Colote, Tournigand, Louvet, Duval, Flejou, de Gramon Tags: Chemotherapy, Translational Oncology Gastrointestinal Cancer Source Type: research

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 [Hematologic Malignancy]
Conclusion Reduced-intensity conditioning HSCT to maintain remission in selected older patients with AML is relatively well tolerated and appears to provide superior outcomes when compared with historical patients treated without HSCT. GVHD and NRM rates were lower than expected. Future transplantation studies in these patients should focus on further reducing the risk of relapse. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Devine, Owzar, Blum, Mulkey, Stone, Hsu, Champlin, Chen, Vij, Slack, Soiffer, Larson, Shea, Hars, Sibley, Giralt, Carter, Horowitz, Linker, Alyea Tags: Leukemia, Biological Therapy Hematologic Malignancy Source Type: research

Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10 [Urologic Oncology]
Conclusion Dose-intensified SRT was associated with low rates of acute grade 2 and 3 GU and GI toxicity. The impact of dose-intensified SRT on QoL was minor, except for a significantly greater worsening in urinary symptoms. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Ghadjar, Hayoz, Bernhard, Zwahlen, Holscher, Gut, Guckenberger, Hildebrandt, Muller, Plasswilm, Papachristofilou, Stalder, Biaggi-Rudolf, Sumila, Kranzbuhler, Najafi, Ost, Azinwi, Reuter, Bodis, Kaouthar, Wust, Thalmann, Aebersold Tags: Clinical Trials Urologic Oncology Source Type: research

Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach [Urologic Oncology]
Purpose The appropriate duration of surveillance for renal cell carcinoma (RCC) after radical or partial nephrectomy remains unknown, and evidence to support current guidelines are lacking. Herein, we provide an approach to surveillance that balances the risk of recurrence versus the risk of non-RCC death. Patients and Methods We identified 2,511 patients who underwent surgery for M0 RCC between 1990 and 2008. Patients were stratified for analysis by pathologic stage (pT1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN1), relapse location (abdomen, chest, bone, and other), age (
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Stewart-Merrill, Thompson, Boorjian, Psutka, Lohse, Cheville, Leibovich, Frank Tags: Urologic Oncology Source Type: research

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme [Radiation Oncology]
This study compared two radiotherapy regimens on the outcome of these patients. Patients and Methods Between 2010 and 2013, 98 patients (frail = age ≥ 50 years and Karnofsky performance status [KPS] of 50% to 70%; elderly and frail = age ≥ 65 years and KPS of 50% to 70%; elderly = age ≥ 65 years and KPS of 80% to 100%) were prospectively randomly assigned to two arms in a 1:1 ratio, stratified by age (
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Roa, Kepka, Kumar, Sinaika, Matiello, Lomidze, Hentati, Guedes de Castro, Dyttus-Cebulok, Drodge, Ghosh, Jeremić, Rosenblatt, Fidarova Tags: Brain Tumors, Radiation Radiation Oncology Source Type: research

Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial [Gynecologic Cancer]
Conclusion These results show that women who have severe menopausal symptoms after ovarian cancer treatment can safely take hormone-replacement therapy, and this may, in fact, infer benefits in terms of OS in addition to known advantages in terms of quality of life. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Eeles, Morden, Gore, Mansi, Glees, Wenczl, Williams, Kitchener, Osborne, Guthrie, Harper, Bliss Tags: Clinical Trials, Combined Modality, Menopausal Symptoms Gynecologic Cancer Source Type: research

Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Jones Tags: COMMENTS AND CONTROVERSIES Source Type: research

Surveillance for Renal Cell Cancer Recurrence: Which Patients Should Undergo Imaging, How Often, and When? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Haas Tags: EDITORIALS Source Type: research

One and Done: A Week of Radiotherapy for Glioblastoma [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Knisely Tags: Geriatric Oncology, Brain Tumors, Radiation, Palliative Care, Radiation Oncology EDITORIALS Source Type: research

To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Lipkowitz, Kohn Tags: Menopausal Symptoms EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 8, 2015 Category: Cancer & Oncology Authors: Kiesewetter, Lukas, Kuchar, Mayerhoefer, Mullauer, Raderer Tags: Biologic Therapy DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to M.-E. Rouge Bugat et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Nightingale, Swartz, Chapman Tags: CORRESPONDENCE Source Type: research

Polypharmacy and Potentially Inappropriate Medication Use Among Senior Adults With Cancer: What Is the Best Approach? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Rouge Bugat, Brechemier, Balardy Tags: CORRESPONDENCE Source Type: research

Reply to C.T. Hiley [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Kleinberg Tags: CORRESPONDENCE Source Type: research

Cognitive Impairment in Survivors of Irradiated Brain Tumors Is Multifactorial: Implications of Polypharmacy With Antiepileptics? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Hiley Tags: CORRESPONDENCE Source Type: research

Reply to G. Keramida et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Barrington, Mikhaeel, Kostakoglu, Meignan, Hutchings, Mueller, Schwartz, Zucca, Fisher, Trotman, Hoekstra, Hicks, O'Doherty, Hustinx, Biggi, Cheson Tags: CORRESPONDENCE Source Type: research

Fallacy of Quantifying Lymphoma Activity by Scaling to the Liver in [18F]Fluorodeoxyglucose Positron Emission Tomography (Deauville criteria) [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Keramida, Peters Tags: CORRESPONDENCE Source Type: research

You've Lived a Good Life [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Curley Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology [SPECIAL ARTICLES]
Personalized medicines hold promise for many diseases. However, demonstrating the clinical efficacy and cost effectiveness of these medicines can be difficult. It is essential that decision-making processes for funding new medicines, including personalized medicines, are both robust and fit for purpose. We will argue that randomized trials of personalized medicines should be routinely supplemented with other research methods, such as observational research and single-arm studies, and that managed-entry funding programs, such as coverage with evidence development, may offer a means of providing early access to technologies ...
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Lewis, Kerridge, Lipworth Tags: Clinical Trials, Cost Effectiveness, Policy Analysis, Ethics SPECIAL ARTICLES Source Type: research

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline [ASCO SPECIAL ARTICLES]
Purpose The American College of Chest Physicians (ACCP) produced an evidence-based guideline on treatment of patients with small-cell lung cancer (SCLC). Because of the relevance of this guideline to American Society of Clinical Oncology (ASCO) membership, ASCO reviewed the guideline, applying a set of procedures and policies used to critically examine guidelines developed by other organizations. Methods The ACCP guideline on the treatment of SCLC was reviewed for developmental rigor by methodologists. An ASCO Endorsement Panel updated the literature search, reviewed the content, and considered additional recommendations....
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Rudin, Ismaila, Hann, Malhotra, Movsas, Norris, Pietanza, Ramalingam, Turrisi, Giaccone Tags: ASCO Guidelines, Non-ASCO Guidelines, Small Cell, Surgery, Radiation, Chemotherapy ASCO SPECIAL ARTICLES Source Type: research

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer [BIOLOGY OF NEOPLASIA]
Conclusion Alterations affecting the mitogen-activated protein kinase pathway are present in the majority of patients with LGS ovarian cancer. Next-generation sequencing analysis revealed deletions and fusions that are not detected by older sequencing approaches. These findings, coupled with the observation that a subset of patients with recurrent LGS ovarian cancer experienced dramatic and durable responses to MEK inhibitor therapy, support additional clinical studies of MEK inhibitors in this disease. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Grisham, Sylvester, Won, McDermott, DeLair, Ramirez, Yao, Shen, Dao, Bogomolniy, Makker, Sala, Soumerai, Hyman, Socci, Viale, Gershenson, Farley, Levine, Rosen, Berger, Spriggs, Aghajanian, Solit, Iyer Tags: Translational Oncology, Signal Transduction, Growth Factors & Receptor, Oncogenes BIOLOGY OF NEOPLASIA Source Type: research

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005 [Neurooncology]
Conclusion Long-term administration of mifepristone was well tolerated but had no impact on patients with unresectable meningioma. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Ji, Rankin, Grunberg, Sherrod, Ahmadi, Townsend, Feun, Fredericks, Russell, Kabbinavar, Stelzer, Schott, Verschraegen Tags: Brain Tumors Neurooncology Source Type: research